Approval · Notice of Compliance 27698 · 2022
COSENTYX: Notice of Compliance 27698
Issued March 1, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27698
- Date
- March 1, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Indication Expansion & New Presentation: COSENTYX (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in patients 6 year and older who are candidates for systemic therapy or phototherapy
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| COSENTYX | Not yet assigned | — |
| COSENTYX | 02525569 | Marketed |
Medicinal ingredients
- SECUKINUMAB 150 MG per ML
- SECUKINUMAB 75 MG per 0.5ML